VaxInnate opens enrollment in Phase 1 clinical trial for seasonal influenza vaccine

The VaxInnate Corporation announced that it has initiated enrollment in a Phase 1 clinical trial to observe the efficacy of its VAX2012Q, a recombinant quadrivalent vaccine against seasonal influenza infection.

The Phase 1 clinical trial is a dose escalation study that seeks to enroll 320 health adults between the ages of 18 and 40 to observe how they respond to intramuscular injection of VAX2012Q over the course of one year. The study participants will be evaluated in-clinic for 21 days, once six months after vaccination and once again one year after vaccination.

VaxInnate is conducting the study to determine the optimal dosage for patients. The corporation expects results to be available at the end of the calendar year and plans to continue development of the vaccine based on the study findings.

"We're pleased to advance VAX2012Q into clinical development with this study which will enable VaxInnate to optimize the dose of this vaccine" President and CEO of VaxInnate Wayne Pisano said. "We believe VAX2012Q has the potential to be an effective and much-needed option for the prevention of seasonal flu which remains a significant public health problem."

VaxInnate developed the VAX2012Q vaccine using its proprietary Toll-like Receptor technology platform. The technology platform genetically fuses the bacterial protein flagellin to vaccine antigens to create an effective vaccine that can enhance an immune response in a patient.

The trial is wholly funded through the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority.